GSK plc executives, including the CEO and other high-level officials, acquired shares on January 8, 2026, by reinvesting dividends, with prices at £18.9433 to £18.9464 per share across various volumes. This filing falls under 'Changes in capital structure' and is considered significant from an equity investor perspective.